Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.9
5.2
Journals
Vaccines
Special Issues
Vaccine Development for Parasitic Disease
share announcement

Vaccine Development for Parasitic Disease

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Attenuated/Inactivated/Live and Vectored Vaccines".

Deadline for manuscript submissions: closed (30 April 2023) | Viewed by 7733

Special Issue Editors

Dr. Qingli Niu

E-Mail Website
Guest Editor
Lanzhou Veterinary Research Institute, Chinese Academic of Agricultural Sciences, Lanzhou, China
Interests: African swine fever virus; molecular mechanism; host–virus interaction; diagnosis; vaccine
Special Issues, Collections and Topics in MDPI journals
Surekha Shridhar

E-Mail Website
Co-Guest Editor
Center for Vaccine Development and Global Health, University of Maryland, 685 W. Baltimore Street, Baltimore, MD 20742, USA
Interests: infectious diseases; vaccine development; microbiology and immunology; protein expression and purification

Special Issue Information

Dear Colleagues,

I am pleased to invite you to submit contributions to a Special Issue focused on human and veterinary vaccine research against well-known and emerging parasites that challenge human or animal health. We welcome articles on the development and evaluation of vaccines against parasitic infections. The scope of this Special Issue covers vaccine engineering, design, formulation, adjuvants, delivery and testing, as well as novel approaches to the discovery and characterization of antigens or small molecules that may be the foundation for novel therapeutics, and their associated immunological evaluations. The full experimental details must be provided so that the results can be reproduced, and any computed data or files regarding the full details of the experimental procedure can be deposited as Supplementary Materials.

I look forward to receiving your contributions.

Dr. Qingli Niu
Surekha Shridhar 
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • human vaccine
  • veterinary vaccine
  • parasites
  • human or animal health
  • vaccine engineering
  • design
  • formulation
  • adjuvants
  • novel therapeutics
  • antigens
  • small molecules

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

10 pages, 1353 KiB  
Article
Immunoprotection Efficacy of Con A-Purified Proteins against Haemonchus contortus in Goats
by Lisha Ye, Yao Zhang, Simin Wu, Zhiheng Wang, Feng Liu, Chunqun Wang and Min Hu
Vaccines 2022, 10(11), 1891; https://doi.org/10.3390/vaccines10111891 - 9 Nov 2022
Cited by 2 | Viewed by 1390
Abstract
Parasitic nematodes are important pathogens that infect animals, causing significant economic losses globally. Current repeated treatments have led to widespread anthelmintic resistance in nematode populations, so vaccine development offers an alternative control approach. However, only one effective vaccine (named Barbervax) has been developed [...] Read more.
Parasitic nematodes are important pathogens that infect animals, causing significant economic losses globally. Current repeated treatments have led to widespread anthelmintic resistance in nematode populations, so vaccine development offers an alternative control approach. However, only one effective vaccine (named Barbervax) has been developed to protect animals against one of the most pathogenic nematodes of ruminants—Haemonchus contortus (the barber’s pole worm). This vaccine contains a dominant component, Concanavalin A (Con A) purified H11 antigen, which has been shown to induce high levels (>85%) of immune protection in sheep breeds, but in goat breeds, the immunoprotection test of this native protein is still lacking. Here, we evaluated the protective efficacy of low-dose Con A-purified proteins for controlling the H. contortus infection in goats. Four-month-old Boer goats were equally divided into two vaccinated groups of 5 μg and 10 μg native proteins, and one adjuvant control. Each goat was immunized subcutaneously thrice and then challenged with 7000 infective third-stage larvae (L3s). The fecal egg count (FEC), degree of anemia, antibody levels of serum and abomasum mucosa, as well as worm burdens, were detected in experimental goats. Our results showed that both 5 μg and 10 μg vaccinated groups induced the effective protection in goats, reduced mean FEC by 71.8% and 68.6%, and mean worm burdens by 69.8% and 61.6%, respectively, compared to the adjuvant control. In addition, we detected that the serum antibody responses to the Con A-purified proteins were dominated by the IgG subtype, but the mucosal antibody responses were not detected. These data demonstrate Con A-purified proteins induced effective immunoprotection in goats, and underline their significance for controlling this widespread parasite. Full article
(This article belongs to the Special Issue Vaccine Development for Parasitic Disease)
►▼ Show Figures

Figure 1

Review

Jump to: Research

12 pages, 715 KiB  
Review
Conserved Candidate Antigens and Nanoparticles to Develop Vaccine against Giardia intestinalis
by Suthinee Sangkanu, Alok K. Paul, Julalak Chuprom, Watcharapong Mitsuwan, Rachasak Boonhok, Maria de Lourdes Pereira, Sonia Marlene Rodrigues Oliveira, Polrat Wilairatana, Mohammed Rahmatullah, Christophe Wiart, Muhammad Nawaz, Chea Sin, Sunil Kayesth and Veeranoot Nissapatorn
Vaccines 2023, 11(1), 96; https://doi.org/10.3390/vaccines11010096 - 31 Dec 2022
Cited by 1 | Viewed by 5921
Abstract
Giardia intestinalis (Giardia lambia, Giardia duodenalis) infections in humans may be asymptomatic or symptomatic and associated with diarrhea (without blood), abdominal cramps, bloating, flatulence, and weight loss. The protozoan Giardia is the third most common cause of diarrhea and death [...] Read more.
Giardia intestinalis (Giardia lambia, Giardia duodenalis) infections in humans may be asymptomatic or symptomatic and associated with diarrhea (without blood), abdominal cramps, bloating, flatulence, and weight loss. The protozoan Giardia is the third most common cause of diarrhea and death in children under five, preceded only by rotavirus and by Cryptosporidium parvum and C. hominis infections. Antimicrobial drugs, particularly 5-nitroimidazole (5-NIs), are used to treat giardiasis in humans. Immunologically naive or immunocompromised host are more vulnerable to Giardia infection, whereas a degree of resistance to this protozoan is present in humans living in endemic areas. This suggests that vaccination may be a potential and appropriate means to control this parasitic disease outbreak and protect the human population. This review discusses Giardia antigens related to vaccine development. Additionally, based on the latest development of nanoparticle technology, a combination of methods for future research and development is proposed for the design of the next generation of powerful immunogens and an effective vaccine against Giardia. Full article
(This article belongs to the Special Issue Vaccine Development for Parasitic Disease)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop